Clinical Trial

A Study of Dotinurad Versus Allopurinol in Participants With Gout

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the efficacy of dotinurad in lowering serum uric acid (sUA) at Week 24 compared with allopurinol in adult participants with hyperuricemia associated with gout.
Protocol Amendment History 2 changes
notable Trial sites expanded: 100 -> 103 locations 2026-07-31
notable Trial sites expanded: 95 -> 100 locations 2026-05-14
Trial Details
NCT Number NCT07089875
Lead Sponsor Crystalys Therapeutics
Conditions Gout
Enrollment 500 participants
Start Date 2025-08-01
Primary Completion 2027-11-29 (estimated)
Study Completion 2027-11-29 (estimated)
Updated on ClinicalTrials.gov 2026-07-30